DLX1 is a homeobox transcription factor that functions as both an activator and repressor of gene expression, with key roles in developmental and disease contexts. During hematopoietic differentiation, DLX1 inhibits cytokine signaling pathways including TGFB1, activin-A, and BMP4 by interfering with transcription factors such as SMAD2 and SMAD3 [UniProt]. In the developing nervous system, DLX1 regulates interneuron terminal differentiation and likely plays a role in ventral forebrain development and GABAergic neuron specification 123. At the population level, DLX1 marks slow-cycling epidermal stem cells whose expansion characterizes skin aging 4. In lung adenocarcinoma (LUAD), DLX1 has emerged as an oncogenic driver. Elevated DLX1 expression correlates with advanced disease stage, TP53 mutations, and poor overall survival 56. Functionally, DLX1 silencing impairs LUAD cell proliferation, invasion, and tumorigenesis in vivo. Mechanistically, DLX1 directly activates the transcriptional target NCS1, which in turn promotes MYC-driven oncogenic pathways 5. Recent evidence suggests DLX1 also contributes to tau-related neurodegeneration in progressive supranuclear palsy through the PERK-B-dependent translation pathway 7. Beyond oncology, DLX1 methylation status shows promise as a biomarker for cervical cancer screening and risk stratification 8.